Pharmacoeconomic Analysis Of Using Cephalosporin Group In Appendicitis Prophylactic In Rumah Sakit Umum Daerah Subang

  • Yulia Wardati Universitas Al-Ghifari
  • Dytha Andri Deswat Universitas Al-Ghifari
  • Zainal Muttaqin Universitas Al-Ghifari
DOI: https://doi.org/10.35814/jifi.v16i2.441

Abstract

The administration of cephalosporin group antibiotics in patients with post-surgical appendicitis is necessary to prevent postoperative wounds. This pharmacoeoconomic study was conducted retrospectively in the period of 1 January to 31 December 2015 in RSUD Subang for the purpose of determining the effectiveness of drugs and the cost of antibiotic use of ceftriaxone, cefotaxime, and ceftizoxime injection by Cost Effectiveness Analysis method. The subject of the patient was 78 people. Based on Average Cost Effectiveness Ratio (ACER), the smallest value is ceftriaxone Rp 729.124 / day, while the result of Cost Effectiveness plane with cefotaxime as standard drug, ceftriaxone occupies quadrant IV and ceftizoxime occupies  quadrant I. The result of Incremental Cost Effectiveness Ratio (ICER) calculation obtained by difference of value equal  to Rp 106.347 / day hence can be concluded that antibiotic injection of cefotaxime as standard injection antibiotics used by RSUD Subang can be replaced by antibiotic injection of ceftizoxim by adding cost Rp 106.347 / day but need attention to resource especially funds owned and should be selected if sufficient resources are available.

References

1. BPOM, 2016. http//pionas.bpom.go.id/ (diakses 28 Maret 2016)

2. Brunner & Suddart.2000. Keperawatan Medical Bedah.EGC : Jakarta

3. Depkes, RI. 2008. Kasus Appendisitis di Indonesiahttp//www.artikelkedokteran.com/arsip/kasus-appendisiti-di-indonesia-padatahun-2008.html ( diakses 7 Maret 2016 )

4. Dorland W. A. Newman. 2000. Dorland’s Illustrated Medical Dictionary. 29th ed. Terjemahan : Huriawati Hartanto. Penerbit Buku Kedokteran EGC. P.142 : Jakarta

5. Kemenkes. 2013. Pedoman Penerapan Kajian Farmakoekonomi

6. Siregar, Charles J, P., 2003.,Farmasi Rumah Sakit., EGC.,Jakarta

7. SIM-RSUD Subang, 2016. Data Pasien Usus Buntu

8. Sjamsuhidayat, R, De Jong, W, 2010. Buku Ajaran Ilmu Bedah. EGC: Jakarta

9. Sri Aisyah Muharti, Muhhamad Muhlis, Woro Supadmi., Analisis Cost Effectiveness Penggunaan Seftriakson dan Sefotaksim Pada Terapi Profilaksis Apendektomi di RS PKU Muhammadiyah Yogyakarta Tahun 2006-2007., Jurnal Ilmiah Kefarmasian., VOL 1., No 2., 2011: 79-89., Universitas Ahmad Dahlan., Yogyakarta

10. Sutedjo, Y.A, 2008. Mengenal Obat-Obatan Secara Mudah dan Aplikasinya Dalam Perawatan. Amara Books: Yogyakarta
Ummualya. 2008. Angka Kejadian Appendisitis.http://digilib.unimus.ac.id/files/disk/136/jtptunimus-gdll-trimuflikh-6753-1.pdf(diakses pada tanggal 2 november 2012)

11. WHO.Global burden diseases.http://www.who.int/healthinfo/global_burden diseases/BD report 2004 update Annex.pdf:2004 (diakses 10 Maret 2016)
Published
2018-10-30
How to Cite
WARDATI, Yulia; DESWAT, Dytha Andri; MUTTAQIN, Zainal. Pharmacoeconomic Analysis Of Using Cephalosporin Group In Appendicitis Prophylactic In Rumah Sakit Umum Daerah Subang. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 16, n. 2, p. 200-205, oct. 2018. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/441>. Date accessed: 05 nov. 2024. doi: https://doi.org/10.35814/jifi.v16i2.441.
Citation Formats
Issue
Vol 16 No 2 (2018): JIFI
Section
Articles

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.